Get started
RIGHT SEASON INVTS CORP.RIGHT SEASON INVTS CORP.RIGHT SEASON INVTS CORP.

RIGHT SEASON INVTS CORP.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

RMANF trade ideas

LITT.V -- Signs DA for a Psychedelics Clinic in CaliforniaThe psychedelics/psilocybin sector is heating up again. MMED.N has gained 100%+ off recent lows and SHRM.C is hitting fresh highs. Not many people know this but LITT.V is a strategic investor in SHRM.C and today it had a significant announcement of its own... Technical chart is a thing of beauty! Strong accumulation with bullish MACD/RSI/Stoch action. Lots of room to run! -------------------------------------------------------------------------------------------------------------------------------- Roadman Investments Signs Definitive Agreement with Psychedelic Insights Solidifying Psychedelics Clinic Investment March 31, 2020 - TheNewswire - VANCOUVER, British Columbia – Roadman Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF) (“Roadman Investments” or the “Company”) is pleased to announce the signing of a definitive agreement with Psychedelic Insights to form a joint venture for the purpose of opening up a legal psychedelic treatment center in the state of California upon the legalization or medical approval of psilocybin. Psychedelic Insights is one of the only companies in the world that offers psychological guided psychedelic experiences with magic psilocybin truffles in their safe psychedelic space in the center of Amsterdam. The company has experienced specialists, a passion for healing people, proven results, mature IT marketing and sales infrastructure with bookings system, CRM, Mail-systems, Screening evaluation, etc. Psychedelic Insights is perfect partner for Roadman as their business is very scalable across jurisdictions. With the liberalisation of drug policies globally we anticipate the need for qualified certified therapists and practitioners to be a major bottleneck to growth. Psychedelic Insights offers a comprehensive training program that will allow the scale across the US as new states approve treatments. Roadman Investments providing capital and Psychedelic Insights providing the expertise and operating the centers. The number of researchers, universities, and other institutions conducting and publishing scientific studies on the healing powers of psychedelics is increasing daily and is at an all-time high. Stigma is dissolving and people are starting to seek out psychedelic experiences and we expect there to be a lot of demand for these mental health services in the future. California is a great starting point for the first Psychedelic Insights Center in the US as the state is very progressive, has the most cities that decriminalized psilocybin in the country and has the largest population. Definitive Agreement Terms - Roadman shall contribute up to $500,000 USD to the partnership in order to launch the center’s operations, which the Company will source from financing or selling of assets. - Roadman Investments and Psychedelic Insights are jointly responsible to manage finances, arranging insurance and deposits, creating a budget, managing expenses and creating financial reports. - Psychedelic Insights shall contribute to establishing the center’s requirements, protocols, patient intakes, promotional marketing, supplier sourcing for needed materials, overall logistical coordination and registration. - Psychedelic Insights is responsible for a high-quality business plan at least 5 months prior to the launch of the clinic - Psychedelic Insights is responsible for the coordination and hiring of mental health professionals to operate the center. Exclusivity Psychedelic insights grant Roadman Investments a 36-month period of exclusivity for the state of California. Neither Psychedelic Insights nor any of its representatives will, at any time solicit, encourage, discuss, negotiate or entertain any proposals from or provide financial, operating or any other non-public information to, any party other than Roadman with respect to the subject matter of the proposed partnership. Equity Interests Each Partner shall be entitled to each item of the Partnership's income, profit, gain, loss, cost, deduction, credit or allowance in proportion to its Partnership Interest listed below: - ROADMAN INVESTMENTS CORP: 51% - PSYCHDELIC INSIGHTS: 40% - FLAGSHIP US CLINIC DIRECTOR: 9% CEO and Director Luke Montaine stated: “Psychedelic Insights is currently one of the few operational psychedelic clinics in the world and have an amazing team that is helping people achieve personal transformations with psychedelics. This agreement will allow both companies to launch, when legally permitted to, and capture a first mover advantage in the country.” In addition, we advise that the Company will be required to secure financing of equity or debt, sell investment assets and/or seek alternative financing methods in order fund the fulfillment of the above disclosed obligations. There is risk that the license or approval for planned treatment center may not be obtained and that if approval is not obtained the Psychedelic Insights Center and joint venture will not exist.
TSXV:LITTLong
by wealth_bakery
LITT.V - Potential breakout brewing on 12M volume & growing bidsSpeculative $5M mkt cap psychedelic mushrooms & Coronavirus spread prevention pharma play. Mostly promo driven but cheap mkt cap given recent developments. - Feb 5, 2020: Signed LOI with Legal Dutch Psilocybin Therapy Center to create JV in California. Expecting to sign DA at the end of February. - Feb 12, 2020: Signed LOI with CLOV Biopharma (specializing in research of cedar leaf oil vapour to prevent the spread of Coronavirus and other pathogenic respiratory viruses). Should be close to done churning through .055 pp shares and profit takers from recent lows. Strong bid support. Today's 12M+ volume was 2nd highest on TSXV and is a potential sign of coming breakout.
TSXV:LITTLong
by wealth_bakery
RMANF New Cannabis Alternative Jumps 21% during Mondays session===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0450 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: Mushrooms. Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound popularized by ’60s counterculture. Oakland, Calif. followed Denver’s lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020. Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The U.S. Food and Drug Administration granted “breakthrough therapy” status in October to Compass Pathways Ltd. to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it’s now proceeding with a large-scale clinical trial in Europe and North America. With their strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”), our latest trade idea RMANF (Roadman Investments Corp.), has cemented themselves as a first mover in a Mushroom Market which is expected to reach USD 34.3 billion by 2024! The Company was recently listed on U.S. exchanges via the OTC, but has been trading on the Toronto and Frankfurt stock exchanges. We are excited to be one of the first financial publications to provide coverage on this industry first mover, and we are urging all of our members to start their research on this IPO style alert immediately. About Roadman Investments Roadman Investments is a Canadian investment firm that strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Roadman is mandated with deploying investment capital and advisory services to both public and private companies. RMANF is engaged in the business of incubating and working with start up entities in with a view to generate capital and generate returns for its shareholders via the tactical deployment of capital across the resource , agricultural, financial services, technology and health and wellness verticals. RMANF Is Currently Focusing On the Following Sectors: Agricultural Financial Services Technology Health and Wellness RMANF is listed on three seperate exchanges: OTC: RMANF |TSX: LITT | FWB:1QD Investment Philosophy RMANF's portfolio selection goes through methodical analysis and our company uses a broad spectrum of investment strategies across industries and capitalization ranges. They analyze not only the financial and business prospects of the companies they invest in but also the fundamental macro drivers of the industry. Investment Criteria Roadman will consider any deal structure if the opportunity is accretive for their portfolio companies. The company focuses on majority acquisitions and minority investments will be considered in special situations. Revenue: $1-10 million EBITDA: $500K- 5 million Industries: Health and Wellness , Agriculture, Financial services and Technology Business Model: Recurring revenue model and Licensing Management: Retention of existing management and key players preferred, but not necessary Location: Worldwide Exposure to emerging industries primed for geometric growth Strong potential for accretive revenue and profitability Ability to generate alpha returns Evidence of potential dominance in market segment and/or geographic location RMANF Is Capitalizing $210B Alternative Health Sector Structural shifts are transforming the health care industry and RMANF is focused on investing in disruptive alternative health companies that offer tremendous potential. RMANF is committed to investing in breakthrough products, devices, treatments and health supplements that promote holistic health and wellness . Yesterday, the Company announced that is has completed a C$150,000.00 strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”). Champignon is a private, research-driven company specializing in the formulation and end distribution of a suite of premium artisanal mushroom health supplements, with the objective of promoting holistic health and wellness . Champignon is equipped with proprietary formulations for three flagship mushroom-extract-infused tea blends and is in the process of conducting extensive taste and product quality tests. The Company invites all current and prospective shareholders to visit the Champignon corporate website by following the below stated URL: champignonbrands.com Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman’s tactical deployment of capital into the burgeoning craft mushroom vertical is indicative of popular opinion shifting within the space. On May 8th, 2019, Denver voters approved Initiative 301, a measure that prohibits the city’s government from deploying resources to impose criminal penalties relating to the consumption and possession of psilocybin by adults over 21 years of age. The passage of Initiative 301 comes amid a recent resurgence in the study of psilocybin and its potential medical applications. Researchers worldwide are increasingly examining whether psilocybin may alleviate symptoms associated with conditions such as anxiety, obsessive-compulsive disorder, major depressive disorder and alcohol dependence. London-based start-up Compass Pathways has produced 20,000 individual doses of psilocybin for use in clinical trials across North America and Europe. Compass boasts an advisory board of esteemed scientists and has attracted high-profile financings from Peter Thiel, Christian Angermayer and Mike Novogratz, among others. Leveraging its newly formed health and wellness committee, Roadman will continue to actively pursue alpha generating investments within this flourishing sector. The global mushroom market accounted for US$38.13 billion in 2017 and is forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. This growth will be further bolstered by the increasing demand for meat substitutes, as well as shifting consumer preference towards vegan foods .” Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL: vitalitysuperteas.com Kevin Matthews, Advisory Board member and Chair of Roadman Investments’ Health and Wellness Committee stated: “We continue to be encouraged by the recent growth within the bourgeoning health and wellness vertical and are actively looking to deploy additional capital into promising, high growth companies. As a result of recent landmark legislative shifts, Roadman’s dedicated Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector, with the objective of augmenting Champignon’s mushroom-extract-infused tea formulations”. www.prnewswire.com THE MUSHROOM MARKET According to market research firm Mordor Intelligence the Global Functional Mushroom Market is expected to reach USD 34.3 billion by 2024 with a CAGR of 8.04%. Much like cannabis before it, psychedelic compounds found in mushrooms have often been maligned by mainstream society. A growing body of evidence shows that chemicals contained in certain mushrooms could be used to treat various mental health problems. ALTERNATIVE TREATMENTS FOR DEPRESSION The World Health Organization projects that there are over 300 million people worldwide dealing with depression.* Research showing the immense benefits of mushroom medicine is growing. The $15 billion-dollar global Anti-Depressant market can be disrupted by chemicals found in mushrooms as treatments go mainstream.* REGULATORY CHANGE In 2018 the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatmentresistant depression. The cities of Denver and Oakland California has voted to decriminalize the fungus that contains psilocybin, a psychedelic compound. The state of Oregon is pushing to get a similar measure on the ballot for 2020 and the wave of regulatory change is projected to continue. Strategic Investment in Champignon Brands Inc. Champignon Brands Inc. is a Canadian based company dedicated to promoting the cultivation and proliferation of high quality medicinal mushrooms and health supplements. Roadman’s executives have been assisting in the product development and commercialization of a proprietary medicinal mushroom infused tea brand. Initial agreement is signed that allows the company to: Appoint a director Inspect records and attend meetings Right of first refusal in any future equity offerings at a price of $0.05 per share or higher Champignon Brands Launches e-Commerce Store Champignon Brands Inc. announced their successful online store launch following a 3-week pilot in the province of British Columbia. The e-commerce store is now offering a selection of medicinal mushroom and tea products. Champignon is currently taking pre-orders for its flagship “Brain Enhance”, “Nourish Force”, “Mighty Re-charge” medicinal mushroom organic teas. The e-commerce store also carries a selection of tea accessories including tea pots, mugs and t-shirts. Roadman’s advisory team has been working closely with the company to optimize the site and has been instrumental in establishing: Store design Product Sourcing Site Speed and SEO optimization Shipment distribution and tracking Checkout Conversion Optimization GEO IP recognition and Currency Conversion Vitality Superteas store can be accessed here: vitalitysuperteas.com Additionally, Champignon has begun advanced discussions with Canadian big box food retailers, as well as prominent wholesalers regarding brick and mortar distribution of its proprietary mushroom-infused tea formulations. Champignon forecasts it will achieve shelf-space for its inaugural SKUs in the third quarter of 2019. The company is working towards establishing a physical pop-up store in a Toronto Coffee shop in the coming months. Luke Montaine, Chief Executive Officer of Roadman Investments: “We excited that under our guidance and advisory Champignon Brand’s inc. has been able to launch their new digital flagship store on schedule. Consumers are becoming more digitally engaged and this store will allow the company to sell it’s products globally and accelerate momentum on their strategy. Roadman Investments is encouraged about the growth in this space and is actively looking to deploy capital into promising and high growth companies. The company’s Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector. RMANF Recent Developments: Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd. In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”). Under the terms of the agreement, Champignon and Drip Coffee will collaborate to formulate a suite of RTD cold brew coffees, as well as barista crafted hot beverage infused with Champignon’s heirloom mushroom-extract blend. Champignon will retain all intellectual property rights associated with the formulations produced under the agreement indefinitely. All formulations produced under the collaboration are expected to be third party tested and boast the following certifications: Vegan; Canadian organic standards; Certified vegan; and, Fair trade certification (“ISO 17065”). Champignon plans to market and sell its mushroom-infused cold brew coffee blends through it’s e-commerce store, direct to consumer, as well as on the shelves of Drip Coffee’s flagship brick and mortar location based in Nanaimo, B.C. Champignon brands plans to encompass a variety of product lines that combine the world’s most powerful superfoods and health supplements. Adding this mushroom infused coffee to the existing Champignon product line will help the company compete more broadly in the industry and expand this previously untapped market niche. Globally, the market for functional mushrooms was valued at $5.8 billion in 2018, according to Avinash Desamangalam, the lead researcher for the food and agriculture department at market intelligence firm Mordor Intelligence, and it is expected to grow 6.4 percent annually from 2019 through 2024, with China expected to be the largest producer and consumer.* Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “We are proud to applaud Champignon’s entrance into the realm of mushroom-infused coffee . Venture Capital backed Four Sigmatic has demonstrated that mushroom enhanced coffee can vastly improve health and wellness and the massive consumer appetitive for this type of product.” .” RMANF Enters Into Advisory Agreement With Canadian Alternative Medicine Incubator, IP Aggregator and Solutions Provider, AltMed Capital Corp RMANF entered into a corporate advisory agreement (the “Advisory Agreement”) with AltMed Capital Corp. (“AltMed”). AltMed is a Canadian alternative medicine business incubator, intellectual property (“IP”) aggregator and solutions provider; mandated with accelerating advancements in the alternative medicine arena. AltMed deploys its diverse network of corporate advisors, clinical practitioners, licensed pharmacists and legal counsel to provide: Development of Standard Operating Procedures (“SOPs”) for drug discovery; Intellectual property formation, advancement and protection; Regulatory advocacy and risk assessment; Clinical trial process development; Sourcing of Qualified Professionals; and Laboratory Testing. AltMed is currently focused on the development of cGMP production and formulation of bioactive compounds extracted from plants and fungi. AltMed aims to leverage its expertise, talent and partnerships to accelerate the pace at which psychedelic compounds are commercialized. Mr. Jay Khetia, a clinical advisor at the Leslie Dan Faculty of Pharmacy, University of Toronto spearheads AltMed’s alternative medicine business incubator and consultancy arm. Mr. Khetia graduated from the Faculty of Pharmacy, University of Brighton with an honours degree in Pharmacy specialising in Pharmacognosy, the study of medicinal plants. Mr. Khetia’s diverse experience includes a role as a staff pharmacist at Boots the Chemist, Pharmacy manager of Moss Chemists in Eastbourne in the United Kingdom and Big Bear Pharmacy where he won the prestigious pharmacy of the year award for Sydney, Australia. Jay currently holds his Pharmacy license in Canada, Australia and England, and strongly believes that alternative health innovations have the potential to treat patients for various chronic diseases, including PTSD, depression and anxiety. Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman is elated to welcome the experienced team at AltMed Capital as an advisory client. Together, the Companies boast access to a robust portfolio of resources, which will further expedite our pursuit in championing material advancements within the alternative medicine arena.” The Advisory Agreement permits the Company to provide advice for corporate actions, including reviewing potential transactions, assisting with alternative financing solutions, and facilitating introductions to strategic partners. Under the terms of the Advisory Agreement, AltMed will compensate the Company C$1,000 for every five-hour block of advisory services provided by the Company or its agents up to a maximum of $20,000 in any one month. Roadman Investments Forms Denver Psychedelic Conference Organizing Committee In September, RMANF formed “The Denver Psychedelic Summit” conference planning committee (the “Committee”). The Denver Psychedelic Summit plans to host numerous high-profile industry leaders and will be held in Denver on the anniversary date of when the first US city decriminalized psilocybin mushrooms. Last year’s ballot initiative in Denver opened a new, grassroots front in the psychedelic renaissance and Roadman Investments wants to help support and be an integral part of that movement. The Committee will work to assemble the conference itinerary including the program sessions, organize speakers and venue to ensure a meaningful event for all attendees. Specific keynote speakers, program and location for the 2020 conference will be announced in the coming months. Psychedelic compounds have often been maligned by mainstream society for their connection with recreational drug use. However, the body of evidence that these chemicals could be used to treat various mental health problems is growing along with investor interest, innovative start-ups and passionate activists. This conference will allow Roadman to find new opportunities to place capital into pioneering companies that are working towards helping people with depression and mental health problems with new breakthrough treatments. Mental illness is one of the biggest causes of the world’s disease burden, with the World Health Organisation (WHO) estimating that over 450 million people are affected by a mental or neurological disorder at some point in their lives*. Modern research is showing that psychedelic medicine may help address the mental health crisis and this summit aims to bring together the leaders moving this new industry forward. CEO and Director Luke Montaine stated: “Denver is becoming a major hub for psychedelics and it is the ideal location for this event. There are so many important developments taking place in this industry and our team is excited to help support the global psychedelic community.” RMANF Issues Corporate Update The Company is also pleased to announce that the Company’s investee Champignon Brands Inc. (“Champignon”) has completed its Series A financing and intends to pursue an Initial Public Offering on the Canadian Securities Exchange in Q4 of 2019. Roadman Investments also announces it has entered into non-disclosure agreements with a variety of health and wellness and alternative medicine focused private companies, of which may result in forthcoming advisory agreements and/or the strategic deployment of capital. Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL: vitalitysuperteas.com Market Outlook The global complementary and alternative medicine market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues. Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period. Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data. The global Mushroom market accounted for US$ 38.13 Bn in 2017, expanding at a CAGR of 7.9% from 2018 to 2026. Rising consumption of processed food items, rising consumer awareness regarding the health benefits offered by mushrooms, and improvement in packaging technologies are some of the key factors influencing the growth of the mushroom market at present. The Bottom Line This is a rare chance to build a position in a company that is new to U.S. exchanges. RMANF is a first-mover in a multi-billion dollar sector. We love these IPO type opportunities, and we are very excited to see the type of growth RMANF is going to have in both the short, and long-term. As such, we are urging all members to act fast, start their research, and make sure to add RMANF to the top of their watchlist! (*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $15,000 cash for a 1-day marketing contract for RMANF . Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
OTC:RMANFLong
by Bullishcharts
RMANF offers Huge Potential in a Cannabis alternative.===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0371 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: Mushrooms. Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound popularized by ’60s counterculture. Oakland, Calif. followed Denver’s lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020. Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The U.S. Food and Drug Administration granted “breakthrough therapy” status in October to Compass Pathways Ltd. to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it’s now proceeding with a large-scale clinical trial in Europe and North America. With their strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”), our latest trade idea RMANF (Roadman Investments Corp.), has cemented themselves as a first mover in a Mushroom Market which is expected to reach USD 34.3 billion by 2024! The Company was recently listed on U.S. exchanges via the OTC, but has been trading on the Toronto and Frankfurt stock exchanges. We are excited to be one of the first financial publications to provide coverage on this industry first mover, and we are urging all of our members to start their research on this IPO style alert immediately. About Roadman Investments Roadman Investments is a Canadian investment firm that strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Roadman is mandated with deploying investment capital and advisory services to both public and private companies. RMANF is engaged in the business of incubating and working with start up entities in with a view to generate capital and generate returns for its shareholders via the tactical deployment of capital across the resource , agricultural, financial services, technology and health and wellness verticals. RMANF Is Currently Focusing On the Following Sectors: Agricultural Financial Services Technology Health and Wellness RMANF is listed on three seperate exchanges: OTC: RMANF |TSX: LITT | FWB:1QD Investment Philosophy RMANF's portfolio selection goes through methodical analysis and our company uses a broad spectrum of investment strategies across industries and capitalization ranges. They analyze not only the financial and business prospects of the companies they invest in but also the fundamental macro drivers of the industry. Investment Criteria Roadman will consider any deal structure if the opportunity is accretive for their portfolio companies. The company focuses on majority acquisitions and minority investments will be considered in special situations. Revenue: $1-10 million EBITDA: $500K- 5 million Industries: Health and Wellness , Agriculture, Financial services and Technology Business Model: Recurring revenue model and Licensing Management: Retention of existing management and key players preferred, but not necessary Location: Worldwide Exposure to emerging industries primed for geometric growth Strong potential for accretive revenue and profitability Ability to generate alpha returns Evidence of potential dominance in market segment and/or geographic location RMANF Is Capitalizing $210B Alternative Health Sector Structural shifts are transforming the health care industry and RMANF is focused on investing in disruptive alternative health companies that offer tremendous potential. RMANF is committed to investing in breakthrough products, devices, treatments and health supplements that promote holistic health and wellness . Yesterday, the Company announced that is has completed a C$150,000.00 strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”). Champignon is a private, research-driven company specializing in the formulation and end distribution of a suite of premium artisanal mushroom health supplements, with the objective of promoting holistic health and wellness . Champignon is equipped with proprietary formulations for three flagship mushroom-extract-infused tea blends and is in the process of conducting extensive taste and product quality tests. The Company invites all current and prospective shareholders to visit the Champignon corporate website by following the below stated URL: champignonbrands.com Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman’s tactical deployment of capital into the burgeoning craft mushroom vertical is indicative of popular opinion shifting within the space. On May 8th, 2019, Denver voters approved Initiative 301, a measure that prohibits the city’s government from deploying resources to impose criminal penalties relating to the consumption and possession of psilocybin by adults over 21 years of age. The passage of Initiative 301 comes amid a recent resurgence in the study of psilocybin and its potential medical applications. Researchers worldwide are increasingly examining whether psilocybin may alleviate symptoms associated with conditions such as anxiety, obsessive-compulsive disorder, major depressive disorder and alcohol dependence. London-based start-up Compass Pathways has produced 20,000 individual doses of psilocybin for use in clinical trials across North America and Europe. Compass boasts an advisory board of esteemed scientists and has attracted high-profile financings from Peter Thiel, Christian Angermayer and Mike Novogratz, among others. Leveraging its newly formed health and wellness committee, Roadman will continue to actively pursue alpha generating investments within this flourishing sector. The global mushroom market accounted for US$38.13 billion in 2017 and is forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. This growth will be further bolstered by the increasing demand for meat substitutes, as well as shifting consumer preference towards vegan foods .” Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL: vitalitysuperteas.com Kevin Matthews, Advisory Board member and Chair of Roadman Investments’ Health and Wellness Committee stated: “We continue to be encouraged by the recent growth within the bourgeoning health and wellness vertical and are actively looking to deploy additional capital into promising, high growth companies. As a result of recent landmark legislative shifts, Roadman’s dedicated Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector, with the objective of augmenting Champignon’s mushroom-extract-infused tea formulations”. www.prnewswire.com THE MUSHROOM MARKET According to market research firm Mordor Intelligence the Global Functional Mushroom Market is expected to reach USD 34.3 billion by 2024 with a CAGR of 8.04%. Much like cannabis before it, psychedelic compounds found in mushrooms have often been maligned by mainstream society. A growing body of evidence shows that chemicals contained in certain mushrooms could be used to treat various mental health problems. ALTERNATIVE TREATMENTS FOR DEPRESSION The World Health Organization projects that there are over 300 million people worldwide dealing with depression.* Research showing the immense benefits of mushroom medicine is growing. The $15 billion-dollar global Anti-Depressant market can be disrupted by chemicals found in mushrooms as treatments go mainstream.* REGULATORY CHANGE In 2018 the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatmentresistant depression. The cities of Denver and Oakland California has voted to decriminalize the fungus that contains psilocybin, a psychedelic compound. The state of Oregon is pushing to get a similar measure on the ballot for 2020 and the wave of regulatory change is projected to continue. Strategic Investment in Champignon Brands Inc. Champignon Brands Inc. is a Canadian based company dedicated to promoting the cultivation and proliferation of high quality medicinal mushrooms and health supplements. Roadman’s executives have been assisting in the product development and commercialization of a proprietary medicinal mushroom infused tea brand. Initial agreement is signed that allows the company to: Appoint a director Inspect records and attend meetings Right of first refusal in any future equity offerings at a price of $0.05 per share or higher Champignon Brands Launches e-Commerce Store Champignon Brands Inc. announced their successful online store launch following a 3-week pilot in the province of British Columbia. The e-commerce store is now offering a selection of medicinal mushroom and tea products. Champignon is currently taking pre-orders for its flagship “Brain Enhance”, “Nourish Force”, “Mighty Re-charge” medicinal mushroom organic teas. The e-commerce store also carries a selection of tea accessories including tea pots, mugs and t-shirts. Roadman’s advisory team has been working closely with the company to optimize the site and has been instrumental in establishing: Store design Product Sourcing Site Speed and SEO optimization Shipment distribution and tracking Checkout Conversion Optimization GEO IP recognition and Currency Conversion Vitality Superteas store can be accessed here: vitalitysuperteas.com Additionally, Champignon has begun advanced discussions with Canadian big box food retailers, as well as prominent wholesalers regarding brick and mortar distribution of its proprietary mushroom-infused tea formulations. Champignon forecasts it will achieve shelf-space for its inaugural SKUs in the third quarter of 2019. The company is working towards establishing a physical pop-up store in a Toronto Coffee shop in the coming months. Luke Montaine, Chief Executive Officer of Roadman Investments: “We excited that under our guidance and advisory Champignon Brand’s inc. has been able to launch their new digital flagship store on schedule. Consumers are becoming more digitally engaged and this store will allow the company to sell it’s products globally and accelerate momentum on their strategy. Roadman Investments is encouraged about the growth in this space and is actively looking to deploy capital into promising and high growth companies. The company’s Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector. RMANF Recent Developments: Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd. In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”). Under the terms of the agreement, Champignon and Drip Coffee will collaborate to formulate a suite of RTD cold brew coffees, as well as barista crafted hot beverage infused with Champignon’s heirloom mushroom-extract blend. Champignon will retain all intellectual property rights associated with the formulations produced under the agreement indefinitely. All formulations produced under the collaboration are expected to be third party tested and boast the following certifications: Vegan; Canadian organic standards; Certified vegan; and, Fair trade certification (“ISO 17065”). Champignon plans to market and sell its mushroom-infused cold brew coffee blends through it’s e-commerce store, direct to consumer, as well as on the shelves of Drip Coffee’s flagship brick and mortar location based in Nanaimo, B.C. Champignon brands plans to encompass a variety of product lines that combine the world’s most powerful superfoods and health supplements. Adding this mushroom infused coffee to the existing Champignon product line will help the company compete more broadly in the industry and expand this previously untapped market niche. Globally, the market for functional mushrooms was valued at $5.8 billion in 2018, according to Avinash Desamangalam, the lead researcher for the food and agriculture department at market intelligence firm Mordor Intelligence, and it is expected to grow 6.4 percent annually from 2019 through 2024, with China expected to be the largest producer and consumer.* Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “We are proud to applaud Champignon’s entrance into the realm of mushroom-infused coffee . Venture Capital backed Four Sigmatic has demonstrated that mushroom enhanced coffee can vastly improve health and wellness and the massive consumer appetitive for this type of product.” .” RMANF Enters Into Advisory Agreement With Canadian Alternative Medicine Incubator, IP Aggregator and Solutions Provider, AltMed Capital Corp RMANF entered into a corporate advisory agreement (the “Advisory Agreement”) with AltMed Capital Corp. (“AltMed”). AltMed is a Canadian alternative medicine business incubator, intellectual property (“IP”) aggregator and solutions provider; mandated with accelerating advancements in the alternative medicine arena. AltMed deploys its diverse network of corporate advisors, clinical practitioners, licensed pharmacists and legal counsel to provide: Development of Standard Operating Procedures (“SOPs”) for drug discovery; Intellectual property formation, advancement and protection; Regulatory advocacy and risk assessment; Clinical trial process development; Sourcing of Qualified Professionals; and Laboratory Testing. AltMed is currently focused on the development of cGMP production and formulation of bioactive compounds extracted from plants and fungi. AltMed aims to leverage its expertise, talent and partnerships to accelerate the pace at which psychedelic compounds are commercialized. Mr. Jay Khetia, a clinical advisor at the Leslie Dan Faculty of Pharmacy, University of Toronto spearheads AltMed’s alternative medicine business incubator and consultancy arm. Mr. Khetia graduated from the Faculty of Pharmacy, University of Brighton with an honours degree in Pharmacy specialising in Pharmacognosy, the study of medicinal plants. Mr. Khetia’s diverse experience includes a role as a staff pharmacist at Boots the Chemist, Pharmacy manager of Moss Chemists in Eastbourne in the United Kingdom and Big Bear Pharmacy where he won the prestigious pharmacy of the year award for Sydney, Australia. Jay currently holds his Pharmacy license in Canada, Australia and England, and strongly believes that alternative health innovations have the potential to treat patients for various chronic diseases, including PTSD, depression and anxiety. Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman is elated to welcome the experienced team at AltMed Capital as an advisory client. Together, the Companies boast access to a robust portfolio of resources, which will further expedite our pursuit in championing material advancements within the alternative medicine arena.” The Advisory Agreement permits the Company to provide advice for corporate actions, including reviewing potential transactions, assisting with alternative financing solutions, and facilitating introductions to strategic partners. Under the terms of the Advisory Agreement, AltMed will compensate the Company C$1,000 for every five-hour block of advisory services provided by the Company or its agents up to a maximum of $20,000 in any one month. Roadman Investments Forms Denver Psychedelic Conference Organizing Committee In September, RMANF formed “The Denver Psychedelic Summit” conference planning committee (the “Committee”). The Denver Psychedelic Summit plans to host numerous high-profile industry leaders and will be held in Denver on the anniversary date of when the first US city decriminalized psilocybin mushrooms. Last year’s ballot initiative in Denver opened a new, grassroots front in the psychedelic renaissance and Roadman Investments wants to help support and be an integral part of that movement. The Committee will work to assemble the conference itinerary including the program sessions, organize speakers and venue to ensure a meaningful event for all attendees. Specific keynote speakers, program and location for the 2020 conference will be announced in the coming months. Psychedelic compounds have often been maligned by mainstream society for their connection with recreational drug use. However, the body of evidence that these chemicals could be used to treat various mental health problems is growing along with investor interest, innovative start-ups and passionate activists. This conference will allow Roadman to find new opportunities to place capital into pioneering companies that are working towards helping people with depression and mental health problems with new breakthrough treatments. Mental illness is one of the biggest causes of the world’s disease burden, with the World Health Organisation (WHO) estimating that over 450 million people are affected by a mental or neurological disorder at some point in their lives*. Modern research is showing that psychedelic medicine may help address the mental health crisis and this summit aims to bring together the leaders moving this new industry forward. CEO and Director Luke Montaine stated: “Denver is becoming a major hub for psychedelics and it is the ideal location for this event. There are so many important developments taking place in this industry and our team is excited to help support the global psychedelic community.” RMANF Issues Corporate Update The Company is also pleased to announce that the Company’s investee Champignon Brands Inc. (“Champignon”) has completed its Series A financing and intends to pursue an Initial Public Offering on the Canadian Securities Exchange in Q4 of 2019. Roadman Investments also announces it has entered into non-disclosure agreements with a variety of health and wellness and alternative medicine focused private companies, of which may result in forthcoming advisory agreements and/or the strategic deployment of capital. Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL: vitalitysuperteas.com Market Outlook The global complementary and alternative medicine market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues. Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period. Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data. The global Mushroom market accounted for US$ 38.13 Bn in 2017, expanding at a CAGR of 7.9% from 2018 to 2026. Rising consumption of processed food items, rising consumer awareness regarding the health benefits offered by mushrooms, and improvement in packaging technologies are some of the key factors influencing the growth of the mushroom market at present. The Bottom Line This is a rare chance to build a position in a company that is new to U.S. exchanges. RMANF is a first-mover in a multi-billion dollar sector. We love these IPO type opportunities, and we are very excited to see the type of growth RMANF is going to have in both the short, and long-term. As such, we are urging all members to act fast, start their research, and make sure to add RMANF to the top of their watchlist! (*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $15,000 cash for a 1-day marketing contract for RMANF . Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
OTC:RMANFLong
by Bullishcharts